Compare · NVO vs OSTX
NVO vs OSTX
Side-by-side comparison of Novo Nordisk A/S (NVO) and OS Therapies Incorporated (OSTX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and OSTX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $187.53B, about 2339.2x OSTX ($80.2M).
- Over the past year, NVO is down 41.7% and OSTX is up 10.4% - OSTX leads by 52.1 points.
- NVO has been more active in the news (11 items in the past 4 weeks vs 9 for OSTX).
- NVO has more recent analyst coverage (25 ratings vs 1 for OSTX).
- Company
- Novo Nordisk A/S
- OS Therapies Incorporated
- Price
- $42.01-2.10%
- $1.80-1.37%
- Market cap
- $187.53B
- $80.2M
- 1M return
- -5.38%
- +8.43%
- 1Y return
- -41.69%
- +10.43%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- AMEX
- IPO
- 2024
- News (4w)
- 11
- 9
- Recent ratings
- 25
- 1
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
- Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates
Latest OSTX
- OS Therapies Achieves Statistically Significant 2.5-Year Overall Survival in Phase 2b Trial of OST-HER2 in Fully Resected Pulmonary Metastatic Osteosarcoma
- OS Therapies Announces the Publication of Four Articles on OST-HER2 and Osteosarcoma in Drug Discovery World
- OS Therapies to Attend Upcoming Medical, Financial and Industry Conferences
- OS Therapies Reports First Quarter 2026 Financials and Provides Business Update
- SEC Form 10-Q filed by OS Therapies Incorporated
- Amendment: SEC Form 5 filed by Romness Paul A.
- SEC Form NT 10-Q filed by OS Therapies Incorporated
- OS Therapies to Announce First Quarter 2026 Financials on Monday, May 18, 2026
- OS Therapies Appoints Industry Leader Dr. Craig Eagle as Chief Medical Advisor
- OS Therapies Incorporated filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits